Nothing said here yet.
to join the conversation.
| Hoge StephenPresident | Sell | 39,145 | $8.6M | Thu, Oct 15 |
| Hoge StephenPresident | Sell | 38,774 | $8.3M | Wed, Oct 14 |
| Hoge StephenPresident | Sell | 450 | $96.4K | Wed, Oct 14 |
| Hoge StephenPresident | Sell | 40,281 | $5.9M | Tue, Sep 15 |
| Hoge StephenPresident | Sell | 40,294 | $5.8M | Mon, Sep 14 |
| Mock James MChief Financial Officer | Sell | 19,836 | $2.7M | Thu, Sep 10 |
| Mock James MChief Financial Officer | Sell | 15,000 | $2.0M | Thu, Sep 10 |
| Klinger Shannon ThymeChief Legal Officer | Sell | 3,471 | $485.8K | Tue, Sep 1 |
| Maria Elvira Salazar | Sell | $8.0K | Thu, Sep 24 | Thu, Oct 1 |
| Maria Elvira Salazar | Buy | $8.0K | Wed, Aug 19 | Tue, Sep 1 |
| Maria Elvira Salazar | Sell | $8.0K | Wed, Aug 19 | Tue, Sep 1 |
Merck and Moderna reported Phase 3 data from the INTerpath-001 trial in resected high-risk melanoma, where personalized mRNA therapy intismeran autogene plus KEYTRUDA reduced the risk of recurrence or death by 42% and distant metastasis or death by 38%…
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.
Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Moderna shares have outperformed tech giants this year.
Shrugging off a valuation downgrade, Moderna (NASDAQ:MRNA) is climbing as investors weigh strong cancer vaccine data against a share price that already reflects big expectations. Moderna stock stands at $217, up 4% this morning.
Axsome's steady ascent has flipped the script—it now outpaces Moderna in quarterly revenue despite starting from a fraction of its size.
For questions about this article or underlying research, email [email protected].
Panmure Liberum believes positive Phase 3 data for a cancer vaccine developed by Moderna and Merck supports the scientific rationale behind Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the cancer immunotherapy developer, and its lead melanoma…